AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Acarbose, metformin studied in GDM. (Oral Agents).
LITTLE ROCK, ARK. -- A landmark study demonstrating the efficacy of glyburide use in gestational diabetes mellitus has given the green light to investigations into the use of other oral hypoglycemic agents during pregnancy Dr. Thomas R. Moore said at the annual meeting of the North American Diabetes in Pregnancy Study Group.
"I really do think that adding insulin to an already hyperinsulinemic / resistant person is the wrong strategy and we should accelerate the search for and safety validation of agents which will modulate insulin resistance. These are presently oral agents, of course. Until then, we will be pouring insulin on the problem as the next best fix," Dr. Moore, professor and chairman of ob.gyn. at the University of California, San Diego, said in an interview
He and his associates are beginning a randomized trial of acarbose plus diet versus diet alone in 200 women with gestational diabetes to see whether the alpha-glucosidase inhibitor can reduce the number of women who need insulin or glyburide therapy
Previous studies have shown that while acarbose itself isn't absorbed ...
- Inhale Announces Preliminary Phase IIb Results of Trial Combining Inhaled...
- Press release article from: Business Wire September 9, 1998 700+ words
...Insulin for Patients Poorly Controlled on Oral Agents Inhale Therapeutic Systems, Inc...failing to control their diabetes with oral agents alone achieved control using pulmonary...pulmonary delivery, while patients using oral agents alone showed little change (9.9...
- Early use of insulin trumps oral agents alone for treating type 2 diabetic...
- Magazine article from: Family Practice News Mahoney, Diana May 1, 2006 700+ words
...improvement among the 23 patients who received oral agents only, after controlling for age, race...patients who did not receive insulin or oral agents experienced a 6% improvement from baseline...the 11 who received both insulin and oral agents experienced a 26% improvement, ...
- Drug update: oral agents for type 2 diabetes. (Clinical Rounds).
- Magazine article from: OB GYN News Zoler, Mitchel L. Tucker, Miriam E. June 1, 2003 700+ words
...sub.1c] value within 2-4 months. Oral agents are usually the first line of drug treatment...these patients can often be switched to oral agents once their glucose levels normalize...SULFONYLUREAS Oldest and cheapest oral agents; long-acting insulin secretagogues...
- New Oral Agents for Multiple Sclerosis, Including Novartis/Mitsubishi Pharma's...
- Press release article from: PR Newswire March 28, 2007 700+ words
...Germany, Italy, Spain, and the United Kingdom. The new Pharmacor report Multiple Sclerosis 2005-2020: Will Emerging Oral Agents Unseat Current Therapies? finds that Novartis/Mitsubishi Pharma's new agent, currently known as fingolimod (also called...
- Launch of Highly Anticipated Oral Agents and Increasing Use of Current and...
- News wire article from: PR Newswire May 26, 2009 700+ words
...research and advisory firms for pharmaceutical and healthcare issues, finds that the approval and launch of highly anticipated oral agents as well as the increasing use of current and emerging injectable drugs will drive the overall multiple sclerosis drug market...
- Joslin Researchers Reveal Mechanisms Behind Class of Oral Agents Used to Treat...
- News wire article from: AScribe Medicine News Service March 9, 2006 700+ words
...Food and Drug Administration-approved agents are known as Actos (pioglitazone) and Avandia (rosiglitazone). These oral agents improve blood glucose levels in people with diabetes by improving insulin action in the body. While it is known that these...
- Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of...
- Press release article from: PR Newswire April 15, 2009 700+ words
...pharmaceutical and healthcare issues, finds that surveyed neurologists anticipate that less than 30 percent of their use of emerging oral agents --- Merck Serono's oral cladribine, Novartis/Mitsubishi Pharma's fingolimod (FTY-720) --- for the treatment...
- Two oral agents benefit type 2 diabetes patients: glimepiride, rosiglitazone...
- Magazine article from: Pediatric News Tucker, Miriam E. July 1, 2005 700+ words
SAN DIEGO -- Two oral glucose-lowering agents that are commonly used in adults with type Z diabetes appeared safe and effective in children in two industry-funded studies presented at the annual scientific sessions of the American Diabetes Association. Although the prevalence of type 2 diabetes
